Dive Brief:
- Johnson & Johnson is betting up to around $3.3 billion on an eye drug that could eventually compete with blockbuster therapies like Roche’s Vabysmo.
- J&J said Monday it will acquire the developer of that medicine, biotechnology startup Ollin Biosciences, for $2.2 billion upfront and another $1.1 billion in milestones. Blackstone Life Sciences is putting up $750 million to support Phase 3 testing of that therapy, OLN324, in wet age-related macular degeneration and diabetic macular edema.
- The acquisition boosts an ophthalmology business that, so far, is largely built around contact lenses, medical devices and surgical equipment. J&J has only dabbled in prescription medicines for ophthalmic conditions, such as through a partnership with gene therapy developer MeiraGTx.
Dive Insight:
Backed by Arch Venture Partners and TCGX, among others, Ollin launched last year with a pair of medicines licensed from China-based drug developers. Both drugs were designed to go after well-known targets and, in theory, offer certain advantages over established treatments.
The drug at the heart of Monday’s deal, OLN324, originated at Shanghai-based Innovent Biologics. Like Roche’s Vabysmo, the drug targets the proteins VEGF and Ang2, both of which help drive the progression of age-related macular degeneration. Ollin, however, has claimed the drug may be more potent and have longer-lasting effects.
The payoff for success could be significant. Vabysmo has become a blockbuster treatment since its initial approval in 2022, and helped steal away market share from Regeneron Pharmaceuticals’ widely used medication Eylea.
The deal also represents a “logical strategic fit” for J&J, given the company’s established presence in eye care, wrote RBC Capital Markets analyst Trung Huynh.
Still, though data from a Phase 1b study supported the drug’s potential, it’s unclear how “differentiated” OLN324 is in what has become a “very competitive and crowded space,” Huynh argued. The price J&J paid “appears high” when compared to the values of other competitors in the space, he added.
Phase 3 studies posted on a federal clinical trial database indicate the company is running two studies in wet AMD and two in diabetic macular edema, all of which compare OLN324 to either Lucentis or Eylea.
“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, J&J’s Ophthalmology Disease Area Stronghold Leader, in a statement. “The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”
The financing deal makes Blackstone eligible for certain milestone payments and royalties should OLN324 make it to market.
Ollin’s other therapy, meanwhile, is a potential competitor to the thyroid eye disease drug Tepezza. That drug, OLN102, is currently in preclinical development.